---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-24-000050"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:30:41.008950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q3 net loss $16.7M; shifts focus to SL-325 DR3 antibody; cash runway into 2027

## Summary
- Net loss of $16.7M ($0.33 per share) vs $27.5M in Q3 2023; no revenue (pre-revenue stage).
- Strategic pivot: discontinuing SL-172154; prioritizing first-in-class DR3 antagonist SL-325 with IND filing expected Q3 2025.
- Cash and investments ~$90.1M as of Sept 30, 2024, expected to fund operations into 2027.
- Substantially completed restructuring (workforce reduction) tied to SL-172154 discontinuation.
- R&D expenses fell to $16.3M from $24.2M; G&A expenses dropped to $4.6M from $5.1M YoY.

## SEC filing metadata
- accession: 0001680367-24-000050
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036724000050/0001680367-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036724000050/sttk-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-24-000050
- JSON: https://secwatch.observer/filing/0001680367-24-000050.json
- Plain text: https://secwatch.observer/filing/0001680367-24-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.